Echoes of Silent Decline: Early Clinical Signals Predicting Rapid Progression of Diabetic Kidney Disease in Adults with Type 2 Diabetes

Matteo Romano¹, Giulia Ferrara²

Abstract

Background:
Diabetic kidney disease (DKD) remains a leading cause of chronic kidney disease and end-stage renal failure worldwide. While traditional markers such as estimated glomerular filtration rate (eGFR) and albuminuria guide risk stratification, many patients experience rapid renal decline despite apparently stable early indicators.

Objective:
To identify subtle early clinical and biochemical signals associated with accelerated DKD progression in adults with type 2 diabetes mellitus (T2DM).

Methods:
A prospective multicenter cohort study was conducted across four tertiary hospitals in Italy between January 2020 and December 2023. A total of 1,284 adults with T2DM and baseline eGFR ≥60 mL/min/1.73 m² were followed for a median of 36 months. Rapid progression was defined as an annual eGFR decline ≥5 mL/min/1.73 m² or progression to CKD stage ≥3. Multivariable Cox regression and predictive modeling were applied.

Results:
During follow-up, 312 patients (24.3%) met criteria for rapid DKD progression. Independent predictors included low-grade persistent inflammation (high-sensitivity CRP ≥3 mg/L; HR 1.82, 95% CI 1.41–2.35), nocturnal systolic blood pressure variability >15 mmHg (HR 1.67, p <0.001), and subtle increases in urinary albumin-to-creatinine ratio within the normoalbuminuric range (HR 1.59, p =0.003). A composite early-risk model demonstrated strong discrimination (AUC 0.87), identifying 78.4% of rapid progressors at baseline. Patients in the highest risk quartile showed a threefold higher progression rate (41.6% vs. 13.9%).

Conclusion:
Early DKD progression is often preceded by quiet yet measurable clinical changes that escape routine assessment. Incorporating inflammatory markers and blood pressure dynamics into early risk models may allow timely intervention and delay irreversible renal decline.